1. Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Relapsed/Refractory NHL Introduction

4. Alpha and Delta PI3K Isoforms

5. CHRONOS-1 Phase 2 Study of Copanlisib in R/R NHL

6. CHRONOS-1 Methods

7. CHRONOS-1 Results

8. CHRONOS-1 Safety

9. ZUMA-1: Phase 2 Study of Axicabtagene Ciloleucel (KTE-C19)

10. ZUMA-1 Safety

11. Examples of Ongoing Clinical Trials of Targeted Therapy in R/R NHL

12. Management of Patients With R/R NHL Using Novel Therapies

13. Abbreviations

14. Abbreviations (cont)